Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday? - EyePoint (NASDAQ:EYPT)

On Monday, EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) announced the topline results of its Phase 2 PAVIA trial evaluating Duravyu (vorolanib intravitreal insert), previously known as EYP-1901, in patients with non-proliferative diabetic retinopathy (NPDR).

The data demonstrated that Duravyu has a biologic effect in patients with NPDR and a favorable safety and tolerability profile; however, the trial did not meet the pre-specified primary endpoint.

The company plans to provide an update on the path forward for Duravyu as a potential treatment in NPDR following a review of the full 12-month data.

PAVIA topline interim results include:

The company remains on track to reach additional clinical milestones with Duravyu, with the initiation of the first Phase 3 pivotal trial in wet AMD, LUGANO, anticipated in the second half of 2024, the second global Phase 3 pivotal trial in wet age-related macular degeneration, LUCIA, to follow, and the readout of topline data from the Phase 2 VERONA trial in diabetic macular edema anticipated in the first quarter of 2025.

Price Action: EYPT shares are down 29.9% at $13.84 during the premarket session at last check Monday.

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.

The data demonstrated that Duravyu has a biologic effect in patients with NPDR and a favorable safety and tolerability profile; however, the trial did not meet the pre-specified primary endpoint.

The company plans to provide an update on the path forward for Duravyu as a potential treatment in NPDR following a review of the full 12-month data.

PAVIA topline interim results include:

86% of patients in the 3mg arm and 80% of patients in the 2mg arm demonstrated stable or improved disease at nine months versus 70% in the control arm.
0% of patients in the 3mg arm and 5% of patients in the 2mg arm worsened ≥2-step at nine months vs. 10% in the control arm.
5% of patients in the 3mg arm and 0% of patients in the 2mg arm achieved a ≥2-step improvement in DRSS score at nine months versus 5% in the control arm.
Continued favorable safety and tolerability profile with no Duravyu-related ocular or systemic serious adverse events reported. No cases of endophthalmitis or retinal vasculitis (occlusive or non-occlusive) were observed.

Price Action: EYPT shares are down 29.9% at $13.84 during the premarket session at last check Monday.

EYPTEyePoint Inc

$14.97-3.04%

Overview

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.